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Efficacy and safety of rituximab  
in patients with active 
proliferative lupus nephritis:  
the Lupus Nephritis Assessment 
with Rituximab Study
Rovin et al., Arthritis Rheum 2012; 64: 1215–1226; doi:10.1002/art.34359
Despite major advances in the therapy of systemic lupus ery-
thematosus, lupus nephritis (LN) remains a major problem. 
Recently, the use of rituximab has been advocated on the 
basis of encouraging results in uncontrolled studies. Now, 
a multicenter study by Rovin et al. has evaluated the effi-
cacy and safety of rituximab in a randomized, double-blind, 
placebo-controlled phase 3 trial in 144 patients with class III 
or class IV LN treated concomitantly with mycophenolate 
mofetil and corticosteroids. The overall (complete and par-
tial) renal response rates were not different—45.8% among 
patients receiving placebo and 56.9% among patients receiv-
ing rituximab. The primary end point, superior response rate 
with rituximab, was not achieved.
In conclusion, although rituximab led to more responders 
and greater reductions in anti-double-stranded DNA and C3/
C4 levels, it did not improve clinical outcomes after 1 year 
of treatment in a controlled trial. Thus, the search for better 
treatment of LN must continue.
Detlef Schlöndorff
Antiplatelet therapy in CKD:  
more harm than benefit?
Palmer et al., Ann Intern Med 2012; 156: 445–459
Antiplatelet agents are used widely to prevent cardiovascular 
events by inhibiting intravascular thrombosis. They have been 
shown to reduce vascular deaths and serious cardiovascular 
events in the general population. This meta-analysis of ran-
domized controlled trials (RCTs) by Palmer et al. examined 
whether treatment effects may differ in patients with various 
stages of chronic kidney disease (CKD) in whom nonathero-
sclerotic conditions are more common causes of cardiovascular 
events, and who have higher bleeding risk. A total of 40 RCTs 
were selected. All were post hoc analyses for the subgroup of 
participants with CKD from larger trials. Nine trials (9969 
participants) provided information on antiplatelet treatment 
in CKD patients who had an acute coronary syndrome or were 
scheduled to undergo coronary artery intervention. Antiplatelet 
treatment consisted of glycoprotein IIb/IIIa inhibitors (abcixi-
mab, eptifibatide, or tirofiban) or clopidogrel. All trials involved 
coadministration of aspirin with or without heparin as non-
randomized interventions. The remaining 31 trials provided 
data for antiplatelet treatment among 11,701 CKD patients 
with stable or no cardiovascular disease, assessing effects on 
mortality, progression of CKD, or safety. These trials involved 
administration of aspirin, dipyridamole, clopidogrel, ticlopi-
dine, sulfinpyrazone, and/or picotamide. The Figure shows 
the sites of pharmacologic inhibition of platelet activity. The 
median follow-up in all trials was 12 months. The meta-analysis 
led to several findings. First, in CKD patients with acute coro-
nary syndromes, glycoprotein IIb/IIIa inhibitors or clopidogrel 
plus standard care compared with standard care alone had lit-
tle or no effect on all-cause or cardiovascular mortality or on 
myocardial infarction. Moreover, it increased serious bleeding. 
Furthermore, in CKD patients with stable or no cardiovascular 
disease, antiplatelet agents prevented myocardial infarction but 
had uncertain effects on mortality and increased minor bleed-
ing, compared with placebo or no treatment. The authors con-
cluded that the benefits of antiplatelet therapy in patients with 
CKD are uncertain and are potentially outweighed by bleeding 
hazards, but overall evidence was weak.
Overview of platelet activation and its inhibition by antiplatelet 
drugs. The platelet has many routes of activation and multiple sites 
of pharmacologic inhibition. Platelet activation is initiated by soluble 
agonists, such as thrombin, thromboxane A2, 5-hydroxytryptamine, 
ADP, and ATP, and by adhesive ligands, such as collagen. Consequently, 
granule secretion of platelet agonists and secretion of thromboxane A2 
lead to amplification of platelet activation and its associated responses. 
Low-dose aspirin inhibits platelet activation via inhibition of the enzyme 
cyclooxygenase 1 (COX1), which reduces the production of thromboxane 
A2, whereas high-dose aspirin inhibits COX2 in endothelial cells, 
thereby suppressing prostacyclin production. By contrast, ADP receptor 
inhibitors, such as clopidogrel, prasugrel, ticagrelor, and cangrelor, 
mediate their actions by inhibiting guanine nucleotide-binding protein-
coupled purinergic receptor P2Y12. aIIbb3, integrin aIIbb3 (also known as 
platelet membrane glycoprotein IIb/IIIa); ADP, adenosine diposphate; 
ATP, adenosine triphosphate; bTG, platelet basic protein (also known 
as b-thromboglobulin); cAMP, cyclic adenosine monophosphate; CCL5, 
CC-chemokine ligand 5 (also known as RANTES); CD40L, CD40 ligand; 
COX, cyclooxygenase (also known as prostaglandin G/H synthase); GPVI, 
glycoprotein VI; 5HT, 5-hydroxytryptamine (also known as serotonin); NO, 
nitric oxide; P2Y12, P2Y12 platelet ADP receptor; PAR, protease activated 
receptor; PDGF, platelet-derived growth factor; PF4, platelet factor 4; 
PGI2, prostacyclin; P-sel, P-selectin; PSGL-1, P-selectin glycoprotein ligand 
1; TGF-b, transforming growth factor-b; TXA2, thromboxane A2; VASP, 
vasodilator-stimulated phosphoprotein.
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Bleeding hazards and lack of clear efficacy in reducing 
cardiovascular morbidity and mortality need to be acknowl-
edged when CKD patients are being counseled about 
antiplatelet therapy.
Tilman B. Drüeke
Hyperfiltration in type 1 diabetes: 
does it exist and does it matter for 
nephropathy?
Thomas et al., Diabetologia 2012; 55: 1505–1513; doi:10.1007/s00125-
012-2485-5
Conventionally, the development of nephropathy in type 1 
diabetes was characterized as an increase in estimated glo-
merular filtration rate (eGFR), which precedes increasing 
albuminuria by several years. This so-called hyperfiltration 
has been regarded as a contributing factor to the development 
of microalbuminuria and progressive nephropathy. Thomas 
et al. examined the association between hyperfiltration and 
progression to microalbuminuria in 2318 adults with type 1 
diabetes and normoalbuminuria from the Finnish Diabetic 
Nephropathy (FinnDiane) Study, a nationwide multicenter 
study of adults with type 1 diabetes. They also compared the 
eGFR in their diabetic patients with rates observed in 6247 
adults from the general population. During a median of 5.2 
years of follow-up, 162 individuals developed microalbumi-
nuria. However, diabetic patients with a higher eGFR were no 
more likely to develop microalbuminuria than those with a 
normal eGFR. This was the case regardless of whether hyper-
filtration was defined as an absolute estimated GFR or deciles 
of eGFR, in men or in women, by the CKD-EPI, MDRD, or 
cystatin C-based estimations. These data suggest that hyper-
filtration does not predict the development of microalbu-
minuria in patients with type 1 diabetes. The results of this 
study are consistent with a recent study of 426 normoalbu-
minuric patients in long-term follow-up at the Joslin Clinic 
that showed no association between hyperfiltration and an 
increased risk of progression to microalbuminuria.1 Moreo-
ver, the distribution of eGFR in adults with type 1 diabetes 
and normoalbuminuria was not significantly different from 
that expected in the general population.
In the absence of incipient or overt nephropathy, renal func-
tion in patients with type 1 diabetes appears to be no different 
from that in the general population. Reduction of the GFR by 
intensive diabetes therapy in the Diabetes Control and Com-
plications Trial (1983 through 1989) was ascribed to a miti-
gation of hyperglycemia-induced hyperfiltration.2 However, 
patients have easy access to insulin and glucose-monitoring 
technologies, and few patients have persistent marked hyper-
glycemia nowadays. The clinical scenario that led to the initial 
observations of ‘hyperfiltration’ in diabetic patients may no 
longer exist in modern clinical practice.
Masaomi Nangaku
1Diabetes Care 2009; 32: 889–893. 2N Engl J Med 2011; 365: 2366–2376.
Cellular therapy comes of age for 
kidney transplantation
Tan et al., JAMA 2012; 307: 1169–1177; doi:10.1001/jama.2012.316
Induction therapy is a routine component of modern kidney 
transplantation that has been shown to reduce acute rejection 
rates in randomized controlled trials (RCTs); however, it is 
associated with increased risk of subsequent development of 
infections and malignancies. Mesenchymal stem cells (MSCs) 
are non-hematopoietic stromal cells with the hallmark property 
of differentiation into mesenchymal tissues (bone, fat, and car-
tilage), which also possess immunosuppressive properties. In 
this RCT, 159 patients undergoing living related kidney trans-
plantation in a single center were studied to compare MSCs 
with anti-interleukin-2 receptor antibody as induction therapy. 
Patients were randomized to receive autologous low-passage 
(3-4 cellular divisions) intravenous bone marrow–derived stem 
cells (1 × 106 to 2 × 106 cells/kg) at induction and 14 days after 
transplantation with standard-dose (n = 53) or ‘low-dose’ cal-
cineurin inhibitor therapy (n = 52) or anti-interleukin-2 recep-
tor antibody (basiliximab, n = 51). Patients receiving MSCs (8% 
and 7%) had a lower rate of biopsy-proven acute rejection than 
those receiving anti-interleukin-2 receptor antibody (22%). 
Renal function as estimated by eGFR was better in the MSC-
treated group in the first week, but not significantly different 
after this time point. When the MSC groups were combined, 
there was a reduction in the risk of development of opportun-
istic infection compared with the control group.
This study by Tan et al. has tested MSCs as induction 
therapy in a group of living-donor transplant recipients in a 
single center and is the first RCT of a cellular therapy as an 
alternative immunomodulatory induction therapy for living 
donor kidney transplantation. The paper raises many mecha-
nistic questions regarding the fate of the infused cells and 
how they protect the allograft. With the short-term follow-
up reported (up to 30 months), we can say that the infusion 
of MSCs appears to be safe. Whether MSCs will definitively 
reduce infection risk and improve long-term outcomes will 
need to be confirmed in larger multicenter trials.
P. Toby Coates
